The latest market report published by Acute Market Reports “Nosocomial Infection Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2024,” the global nosocomial infection treatment market was valued at US$ 28,565 Mn in 2015, and is expected to reach US$ 36,746 Mn by 2024, expanding at a CAGR of 2.5% from 2016 to 2024.
Browse the full report Nosocomial Infection Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2024 report at https://www.acutemarketreports.com/report/nosocomial-infection-treatment-market
Market Insights
Nosocomial infection, also known as hospital acquired or associated infection (HAI) is defined as an infection developed in patients during the hospital stay that was earlier not present or incubated during admission in the hospital. Nosocomial infection is majorly caused by bacteria, virus, or fungal pathogen and is becoming the leading cause of morbidity and mortality globally, causing enormous economic burden. The nosocomial infection treatment market is anticipated to grow throughout the forecast period. Major factors contributing to the growth of the HAI market is rising prevalence of the nosocomial infection, increasing government initiatives and rising public awareness related to the quality hygiene in hospitals, rising geriatric population immuno-compromised patient, advances in air handling units and other cleaning technologies. Multi-drug resistance is observed in patients mainly due to excessive use of antibiotic which is one of the causes of rising prevalence of nosocomial infection. The regulatory authorities have created set of guidelines for hospitals and clinics and instructed them to abide by these guidelines for prevention of nosocomial infection and adopt best health practices along with a devised strategy to control infections.
The global nosocomial infection treatment market are segmented by infection type as pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA, others. Pneumonia, urinary tract infection (UTI), surgical site infection (SSI) and MRSA are the major types of hospital acquired infections that find the highest prevalence.
Nosocomial infection treatment market is segmented on the basis of treatment type as antibacterial, antifungal, antiviral treatment and others. Antibacterial treatment accounted for the largest market share in 2015. As of the current market scenario, North America is the largest regional market for nosocomial infection treatment, followed by Europe and Asia Pacific. North America dominates the global nosocomial infection treatment market attributed to rise in prevalence of nosocomial infections, mounting cases of multi-drug resistant microbial infections and rising demand for advanced therapeutics. Asia Pacific is anticipated to be the fastest growing market during the forecast period. The key factors responsible for its significant growth are emerging economies with developing healthcare market due to pouring investments in healthcare infrastructure by public and private sector, increase in prevalence of nosocomial infection, and high health awareness coupled with growing disposable income.
Market Competition Assessment:
Key players in the nosocomial infection treatment market are
Abbott Vascular Inc., Bayer, Becton, Dickinson and Company, Belimed, BioMerieux, Cantel, Cepheid, Getinge Group, Kimberly-Clark Corp., Merck & Co, Nordion, Pfizer, Roche, Sakura Seiki, BioMérieux, Steris, Johnson & Johnson, Sterigenics International, Inc., Halyard Health, Inc., Advanced Sterilization Products, Matachana Group etc.
Key Market Movements:
